Japanese Encephalitis Vaccine
Japanese Encephalitis
Japanese Encephalitis (JE) is a viral encephalitis transmitted by Culex mosquitoes in Asia and the Western Pacific. The vast majority of infections (99%+) are asymptomatic. However, when symptomatic encephalitis develops, 20–30% of patients die and 30–50% of survivors suffer permanent neurological or psychiatric sequelae. There is no specific treatment — supportive care only. Approximately 68,000 cases of JE occur annually.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →Worth careful consideration. Disease risk in your scenario is lower than average, or the vaccine risk/uncertainty is somewhat higher. Discuss timing and priorities with your provider.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Japanese Encephalitis (JE) is a viral encephalitis transmitted by Culex mosquitoes in Asia and the Western Pacific. The vast majority of infections (99%+) are asymptomatic. However, when symptomatic encephalitis develops, 20–30% of patients die and 30–50% of survivors suffer permanent neurological or psychiatric sequelae. There is no specific treatment — supportive care only. Approximately 68,000 cases of JE occur annually.
JE encephalitis causes fever, seizures, altered consciousness, and paralysis. Survivors frequently suffer cognitive impairment, motor disabilities, behavioral changes, and epilepsy. In a disease with no treatment, the impact on lifetime quality of life is profound — especially given that most cases occur in children under 15. Caregiver burden is substantial in affected communities.
🛡️ Vaccine Effectiveness
Two-dose primary series (Ixiaro) provides robust protection. Seroprotection persists for at least 12–24 months; a booster at 12 months is recommended for ongoing risk. Children vaccinated in Asia with SA 14-14-2 appear to have durable long-term immunity after 2 doses.
Vaccine failures are extremely rare. Virtually all JE cases in vaccinated individuals have occurred following significant immunosuppression or incomplete vaccination.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
If only 1 week before travel: accelerated schedule (Day 0 and Day 7) is FDA-approved for adults 18–65. Booster at 12 months for ongoing risk. Recommended for travelers spending ≥1 month in endemic regions during transmission season, or shorter trips with extensive outdoor/rural exposure.
⚖️ Benefits vs. Considerations
✓ Benefits
- Near-complete (98–99%) protection against a disease with 20–30% mortality and 40–50% permanent neurological disability rate
- No treatment exists for JE — prevention is the only option
- Excellent safety profile with Ixiaro (modern inactivated vaccine)
- 35+ years of use of SA 14-14-2 in Asia covering hundreds of millions of doses
- One-time traveler series (plus booster) provides multi-year protection
↕ Considerations
- Most US residents have negligible exposure risk — relevant primarily for travelers and expats
- Requires 2-dose series ideally completed 1 month before travel
- Cost can be significant ($250–400 for 2-dose traveler series)
- Older JE vaccine (JE-VAX) had significant hypersensitivity risk — modern Ixiaro is much improved
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- The original Japanese JE vaccine (mouse-brain derived) carried a small but real risk of hypersensitivity reactions and has been replaced by modern cell-culture vaccines, but some countries still use older formulations in public programs due to cost. Advocates for universal modern vaccine access argue this creates unequal protection (Halstead & Thomas, 2011).
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Duration of booster immunity after the 12-month booster dose
- Effectiveness of accelerated 0/7-day schedule vs. standard 0/28-day schedule in terms of long-term immunity
- Whether climate change-driven northward expansion of Culex mosquitoes will change the risk profile for travelers to traditionally lower-risk regions
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.